Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.31 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.31 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.31 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.31 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.31 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.31 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.31 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.31 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.31 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.31 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.31 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21994866 | 1.00 | AVPR1A (0.33) | AVPR1AFDFT1MC4RPSMB11PSMA7 | |
| SCHEMBL21994862 | 1.00 | AVPR1A (0.33) | AVPR1AFDFT1MC4RPSMB11PSMA7 | |
| SCHEMBL21994670 | 0.81 | DPP4 (0.33) | AVPR1AFDFT1MC4RLTA4HALDH1A1 | |
| SCHEMBL21994665 | 0.81 | DPP4 (0.33) | AVPR1AFDFT1MC4RLTA4HALDH1A1 | |
| SCHEMBL21994480 | 0.79 | FDFT1 (0.37) | FDFT1LTA4HALDH1A1 | |
| SCHEMBL21994482 | 0.79 | FDFT1 (0.37) | FDFT1LTA4HALDH1A1 | |
| SCHEMBL21994387 | 0.78 | KMT2A (0.38) | FDFT1ALDH1A1 | |
| SCHEMBL21994827 | 0.78 | KMT2A (0.38) | FDFT1ALDH1A1 | |
| SCHEMBL26951790 | 0.76 | MAOB (0.33) | AVPR1AMC4RLTA4HC5AR1 | |
| SCHEMBL21995147 | 0.71 | KMT2A (0.40) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | AVPR1A 438/4885FDFT1 1274/4885MC4R 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.